Additional Relevant Details Celgene expects to complete four phase 3 studies of abraxane in four different indications.  Two studies are sponsored by Roche and study abraxane in combination with atezolizumab in squamous and non-squamous non-small cell lung cancer.  The other two study abraxane treatment on pancreatic cancer and squamous NSCLC maintenence.  Data for all studies expected to release 2017.